Welcome to our dedicated page for Artelo Biosciences news (Ticker: ARTL), a resource for investors and traders seeking the latest updates and insights on Artelo Biosciences stock.
Artelo Biosciences, Inc. develops clinical-stage therapeutics that modulate lipid-signaling pathways, including programs tied to the endocannabinoid system and fatty acid-binding proteins. Company news commonly covers pipeline updates for ART27.13 and ART26.12, including cancer anorexia-cachexia, neuropathic pain, glaucoma, dermatologic, neurological and other inflammation-related indications.
Recurring developments include FABP5 inhibitor research, peer-reviewed publications, collaborations using biological-data analysis, preclinical and clinical program disclosures, patent activity, and externally funded studies. Artelo news also includes capital-structure actions such as private placements, common stock and warrant offerings, and Nasdaq listing-compliance matters.
Artelo Biosciences (Nasdaq: ARTL) reported new preclinical data for ART26.12, a selective FABP5 inhibitor in Phase 1 development, in a mouse model of spinal cord injury neuropathic pain.
According to Artelo, FABP5 inhibition reduced mechanical hypersensitivity, decreased spontaneous pain behaviors, suppressed nociceptor hyperexcitability, and improved pain outcomes after oral dosing.
Artelo Biosciences (Nasdaq: ARTL), a clinical-stage pharmaceutical company, reported new multi-omics data on ART26.12, its selective FABP5 inhibitor, at the ICRS 2026 symposium in Dijon, France.
According to Artelo Biosciences, analyses across multiple disease models showed consistent modulation of the pro-inflammatory lipid linoleic acid and related lipid-signaling pathways, suggesting a potential mechanistic link for FABP5 inhibition’s broad therapeutic activity and supporting ongoing Phase 1 development.
Artelo Biosciences (Nasdaq:ARTL) reported Phase 1 first-in-human data for ART26.12, a selective FABP5 inhibitor, at ICRS 2026. Single ascending oral doses in healthy volunteers were generally well-tolerated and showed linear, dose-dependent pharmacokinetics with dose-proportional systemic exposure.
ART26.12 plasma levels exceeded projected therapeutic concentrations from preclinical studies, with a wide margin between anticipated therapeutic exposure and maximum tolerated doses. AI- and machine learning–driven analyses of proteomic and lipidomic data identified treatment-related changes across multiple biological pathways, supporting development of pharmacodynamic biomarkers.
Artelo Biosciences views these clinical and translational findings as important progress for ART26.12 and follow-on FABP5 inhibitors, including potential non-opioid applications in painful neuropathies.
Artelo Biosciences (Nasdaq: ARTL) reported new human metabolite data for its FABP inhibitor ART26.12 from a completed Single Ascending Dose study in healthy volunteers. Only three metabolites were detected after a 900 mg oral dose, representing about 7% of total drug-related exposure.
The main metabolite accounted for ~5% of exposure and showed biological activity comparable to ART26.12. All three metabolites had been seen and qualified in nonclinical toxicology species. According to Artelo, this low metabolite burden, along with prior favorable safety and pharmacokinetics, supports continued clinical development of ART26.12 for pain.
Artelo Biosciences (Nasdaq: ARTL) reported Q1 2026 results and highlighted clinical milestones expected through 2027. The company is advancing ART26.12 in pain with positive Phase 1 single ascending dose and food-effect data and plans a multiple ascending dose study starting enrollment in Q4 2026.
ART27.13 showed encouraging interim Phase 2 CAReS data in cancer-related anorexia, with gains in body weight, lean body mass, and physical activity. Q1 2026 R&D expenses were $0.8M, G&A $1.9M, net loss $3.0M, and cash and investments $10.3M.
Artelo Biosciences (Nasdaq: ARTL) announced a strategic collaboration with AI company ScienceMachine to accelerate development of its FABP5 inhibitor program, including lead candidate ART26.12.
ScienceMachine applied AI to Artelo’s Phase 1 single ascending dose dataset (ART26.12-100) and multi-omic disease models, identifying candidate proteins indicative of FABP5 target engagement, dose-responsive protein and lipid signatures linked to analgesia, and psoriasis-model results planned for publication later in 2026.
Artelo (Nasdaq: ARTL) announced a peer‑reviewed publication in the European Journal of Pain supporting FABP5 inhibition and preclinical evidence for its candidate ART26.12 as a non‑opioid pain treatment. ART26.12 showed analgesic effects across multiple pain models and seven prior preclinical studies.
The company reported its Phase 1 single ascending dose study had no drug‑related severe or serious adverse events, and a multiple ascending dose study is planned for 2026.
Artelo Biosciences (Nasdaq: ARTL) announced Nasdaq has confirmed the company has regained compliance with Listing Rules 5550(b)(1) and 5620(a). The company held a reconvened annual meeting on January 30, 2026, and regained equity-rule compliance as noted in a March 30, 2026 filing.
In accordance with Listing Rule 5815(d)(4)(B), Artelo will be subject to a mandatory panel monitor for one year. Management reiterated focus on advancing clinical candidates ART27.13 and ART26.12 and pursuing partnership discussions.
Artelo Biosciences (Nasdaq: ARTL) closed a private placement on March 30, 2026, issuing 3,188,407 shares (or pre-funded warrants) and warrants to buy up to 6,376,814 shares at a combined price of $3.45 per share/warrant, generating approximately $11.0 million gross proceeds before fees.
The company intends to use net proceeds for working capital, general corporate purposes, and repayment of certain bridge debt. If all warrants are exercised for cash, potential additional gross proceeds could be about $20.4 million; exercise is not assured.
Artelo Biosciences (Nasdaq: ARTL) entered definitive agreements for a private placement expected to close on or about March 30, 2026. The offering comprises 3,188,407 common shares (or pre-funded warrants) and warrants to buy 6,376,814 shares at $3.20, at a combined purchase price of $3.45 per unit.
Gross proceeds are expected to be approximately $11.0 million before fees; warrants could generate approximately $20.4 million if fully exercised. H.C. Wainwright is exclusive placement agent. Net proceeds will fund working capital, general corporate purposes, and repayment of bridge debt.